NLRP3 inflammasome-driven IL-1β and IL-18 contribute to lipopolysaccharide-induced septic cardiomyopathy-Reference-Cited by-同舟云学术

NLRP3 inflammasome-driven IL-1β and IL-18 contribute to lipopolysaccharide-induced septic cardiomyopathy

Published:2023-07 Issue: Volume:180 Page:58-68
ISSN:0022-2828
Container-title:Journal of Molecular and Cellular Cardiology
language:en
Short-container-title:Journal of Molecular and Cellular Cardiology

Author:

Fujimura Kenta,Karasawa Tadayoshi,Komada Takanori,Yamada Naoya,Mizushina Yoshiko,Baatarjav Chintogtokh,Matsumura Takayoshi,Otsu Kinya,Takeda Norihiko,Mizukami Hiroaki,Kario Kazuomi,Takahashi Masafumi

Funder

Japan Society for the Promotion of Science

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Molecular Biology

Reference34 articles.

1. Severe sepsis and septic shock;Angus;N. Engl. J. Med.,2013

2. Sepsis therapies: learning from 30 years of failure of translational research to propose new leads;Cavaillon;EMBO Mol Med,2020

3. The cardiovascular response of normal humans to the administration of endotoxin;Suffredini;N. Engl. J. Med.,1989

4. Sepsis-induced cardiomyopathy: a comprehensive review;L’Heureux;Curr. Cardiol. Rep.,2020

5. Pathophysiology of sepsis-induced cardiomyopathy;Hollenberg;Nat. Rev. Cardiol.,2021

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of pyroptosis mechanism and in-depth analysis of cardiomyocyte pyroptosis mediated by NF-κB pathway in heart failure;Biomedicine & Pharmacotherapy;2024-10

2. Role of gasdermin D in inflammatory diseases: from mechanism to therapeutics;Frontiers in Immunology;2024-08-26

3. Cardiomyocyte mitochondrial mono-ADP-ribosylation dictates cardiac tolerance to sepsis by configuring bioenergetic reserve;2024-08-01

4. Inflammasome-Mediated Mechanisms Of Systemic Inflammation In COVID-19 And Asthma;Russian Open Medical Journal;2024-06-28

5. Epigallocatechin-3-gallate Inhibits LPS/AβO-induced Neuroinflammation in BV2 Cells through Regulating the ROS/TXNIP/NLRP3 Pathway;Journal of Neuroimmune Pharmacology;2024-06-18